Ourania Tatsis - 17 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
17 Feb 2023
Net transactions value
-$1,458,241
Form type
4
Filing time
22 Feb 2023, 15:48:42 UTC
Previous filing
16 Feb 2023
Next filing
28 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $1,317,239 -4,498 -6.9% $292.85 60,947 17 Feb 2023 Direct
transaction VRTX Common Stock Sale $1,164 -4 -0.01% $291.01 60,943 21 Feb 2023 Direct F1
transaction VRTX Common Stock Sale $42,463 -145 -0.24% $292.85 60,798 21 Feb 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $60,823 -207 -0.34% $293.83 60,591 21 Feb 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $36,551 -124 -0.2% $294.77 60,467 21 Feb 2023 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
F2 Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $292.85 (range $292.37 to $293.36).
F4 Open market sales reported on this line occurred at a weighted average price of $293.83 (range $293.39 to $294.38).
F5 Open market sales reported on this line occurred at a weighted average price of $294.77 (range $294.42 to $295.37).